Navigation Links
Sinovac to Participate in Two Upcoming Investor Conferences
Date:10/29/2008

BEIJING, Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it is scheduled to present at two upcoming investor conferences, including the Oppenheimer 19th Annual Healthcare Conference in New York City and the Credit Suisse Asian Healthcare Conference in Beijing, China.

Ms. Vanessa Wu, Senior Financial Manager, is scheduled to present on Tuesday, November 4, 2008 at 3:20 pm at Oppenheimer 19th Annual Healthcare Conference, at the Waldorf-Astoria Hotel in New York, NY.

Dr. Weidong Yin, Chairman, President and CEO, is scheduled to attend the Credit Suisse Asian Healthcare Conference on November 5 and 6, at The Westin Beijing Hotel at Financial Street in Beijing, China.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7017

Email: scarrington@theruthgroup.com

Janine McCargo

The Ruth Group

Tel: +1-646-536-7033

Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
2. Sinovac Biotech Holds 2007 Annual General Meeting
3. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
4. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
5. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
6. Sinovac Adjourns Annual General Meeting
7. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
8. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):